JP2023553538A5 - - Google Patents
Info
- Publication number
- JP2023553538A5 JP2023553538A5 JP2023560246A JP2023560246A JP2023553538A5 JP 2023553538 A5 JP2023553538 A5 JP 2023553538A5 JP 2023560246 A JP2023560246 A JP 2023560246A JP 2023560246 A JP2023560246 A JP 2023560246A JP 2023553538 A5 JP2023553538 A5 JP 2023553538A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aqueous pharmaceutical
- composition according
- arginine
- contain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125277P | 2020-12-14 | 2020-12-14 | |
| US63/125,277 | 2020-12-14 | ||
| US202163186684P | 2021-05-10 | 2021-05-10 | |
| US63/186,684 | 2021-05-10 | ||
| PCT/US2021/063086 WO2022132636A1 (en) | 2020-12-14 | 2021-12-13 | High concentration formulations of anti-csf1 and anti-csf1r antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553538A JP2023553538A (ja) | 2023-12-21 |
| JP2023553538A5 true JP2023553538A5 (cg-RX-API-DMAC7.html) | 2024-12-12 |
Family
ID=81942250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560246A Pending JP2023553538A (ja) | 2020-12-14 | 2021-12-13 | 抗csf1および抗csf1r抗体の高濃度製剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US11419822B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4065161A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023553538A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022132636A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023553538A (ja) | 2020-12-14 | 2023-12-21 | エーマックス バイオ, インコーポレイテッド | 抗csf1および抗csf1r抗体の高濃度製剤 |
| EP4337257A1 (en) * | 2021-05-12 | 2024-03-20 | AnaptysBio, Inc. | Antibody composition |
| EP4384277A4 (en) * | 2021-08-12 | 2025-07-23 | Ammax Bio Inc | TARGETED DELIVERY OF ANTI-CSF1R ANTIBODIES |
| CN122404563A (zh) * | 2026-06-18 | 2026-07-17 | 南京浦光生物科技有限公司 | 一种基于分子玻璃化外壳技术的抗体冻干球及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトc−fms抗原結合性タンパク質 |
| WO2011017070A1 (en) | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| US20110158987A1 (en) * | 2009-12-29 | 2011-06-30 | F. Hoffmann-Laroche Ag | Novel antibody formulation |
| EP3157957A1 (en) * | 2014-06-23 | 2017-04-26 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US10040858B2 (en) * | 2014-12-22 | 2018-08-07 | Five Prime Therapeutics, Inc. | Anti-CSF1R antibodies for treating PVNS |
| AU2020283742A1 (en) * | 2019-05-24 | 2021-09-16 | Elixiron Immunotherapeutics (hong Kong) Limited | Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof |
| JP2023553538A (ja) | 2020-12-14 | 2023-12-21 | エーマックス バイオ, インコーポレイテッド | 抗csf1および抗csf1r抗体の高濃度製剤 |
-
2021
- 2021-12-13 JP JP2023560246A patent/JP2023553538A/ja active Pending
- 2021-12-13 US US17/549,785 patent/US11419822B2/en active Active
- 2021-12-13 EP EP21907560.3A patent/EP4065161A4/en active Pending
- 2021-12-13 WO PCT/US2021/063086 patent/WO2022132636A1/en not_active Ceased
-
2022
- 2022-05-18 US US17/747,844 patent/US12178915B2/en active Active
-
2024
- 2024-11-19 US US18/952,613 patent/US20250073170A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7715635B2 (ja) | イズロン酸2-スルファターゼを含むタンパク質分子の製剤 | |
| TWI459961B (zh) | 長效人類生長激素共軛物之液態配方 | |
| ES2900624T3 (es) | Formulación de anticuerpos | |
| US7879805B2 (en) | High temperature stable peptide formulation | |
| CN103998060B (zh) | 使用糖与多元醇的结合物稳定的依那西普制剂 | |
| JP7229999B2 (ja) | ダプトマイシン製剤 | |
| EP3681483B1 (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| KR20130028894A (ko) | 항체의 제제 | |
| US9125893B2 (en) | Highly concentrated anti-CD40 antibody pharmaceutical preparation | |
| JP2022105056A (ja) | 高濃度の抗vegf抗体を含有するタンパク質溶液製剤 | |
| JP2019512012A5 (cg-RX-API-DMAC7.html) | ||
| JP2013525406A (ja) | 安定mia/cd−rap製剤 | |
| JP2025087851A (ja) | 安定な低粘度抗体製剤およびその使用 | |
| KR20220034053A (ko) | 재조합 단백질의 안정적인 제형 | |
| EP3373953A1 (fr) | Composition a action rapide d'insuline comprenant un citrate substitue | |
| US11744902B2 (en) | Targeting technology to selectively express mRNAs in cardiomyocytes while avoiding stimulation of cardiac fibroblasts | |
| EP3207936B1 (en) | Stable peptide composition | |
| JPH1180021A (ja) | バンコマイシン注射剤 | |
| TR2023017070T (tr) | Pharmaceutical compositions of bevacizumab | |
| HK40033832B (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| HK40033832A (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| EA043419B1 (ru) | Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка |